ABEGAIL SUMAGUI: Open Payments
NPI 1245937366 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$342 in 13 payments from 7 companies in 2025. Trend: 2023 $223 · 2024 $641 · 2025 $342
Food & beverage: $342
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $82 |
| E.R. Squibb & Sons, L.L.C. | 3 | $74 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 1 | $32 |
| Exact Sciences Corporation | 1 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
Products named: INGREZZA, COBENFY, ABILIFY MAINTENA, INVEGA SUSTENNA, Cologuard Collection Kit, CAPLYTA, AUSTEDO XR, UZEDY.
Industry payments across IL — which companies pay providers there.
